Tesaro Inc. (TSRO) Price Target Raised to $120.00
Tesaro Inc. (NASDAQ:TSRO) had its target price hoisted by Robert W. Baird from $105.00 to $120.00 in a research report report published on Monday morning. They currently have an outperform rating on the biopharmaceutical company’s stock.
Several other equities research analysts also recently issued reports on TSRO. Zacks Investment Research downgraded Tesaro from a hold rating to a sell rating in a report on Wednesday, June 15th. FBR & Co increased their price target on Tesaro from $65.00 to $93.00 and gave the stock an outperform rating in a report on Wednesday, June 29th. Jefferies Group downgraded Tesaro from a buy rating to a hold rating and increased their price target for the stock from $53.00 to $75.00 in a report on Thursday, June 30th. They noted that the move was a valuation call. Leerink Swann increased their price target on Tesaro from $65.00 to $95.00 and gave the stock an outperform rating in a report on Thursday, June 30th. Finally, Mizuho restated an outperform rating and issued a $67.00 price target on shares of Tesaro in a report on Thursday, June 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. Tesaro has a consensus rating of Buy and a consensus price target of $110.11.
Shares of Tesaro (NASDAQ:TSRO) opened at 114.77 on Monday. Tesaro has a 12-month low of $29.51 and a 12-month high of $122.89. The firm’s market capitalization is $5.90 billion. The company has a 50-day moving average price of $98.16 and a 200 day moving average price of $70.43.
Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.43. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. The firm had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. During the same quarter in the prior year, the firm posted ($1.51) earnings per share. Equities research analysts expect that Tesaro will post ($7.36) earnings per share for the current fiscal year.
In other Tesaro news, VP Edward C. English sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $88.54, for a total value of $619,780.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares in the company, valued at $309,890. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Martin H. Jr. Huber sold 408 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total value of $44,112.96. Following the completion of the transaction, the senior vice president now owns 1,250 shares of the company’s stock, valued at $135,150. The disclosure for this sale can be found here. 40.50% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in TSRO. Tocqueville Asset Management L.P. boosted its stake in Tesaro by 28.8% in the second quarter. Tocqueville Asset Management L.P. now owns 31,750 shares of the biopharmaceutical company’s stock worth $2,669,000 after buying an additional 7,100 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Tesaro during the second quarter worth about $240,000. Smith Asset Management Group LP acquired a new stake in Tesaro during the second quarter worth about $406,000. Parametrica Management Ltd boosted its stake in Tesaro by 144.9% in the second quarter. Parametrica Management Ltd now owns 13,988 shares of the biopharmaceutical company’s stock worth $1,176,000 after buying an additional 8,277 shares during the last quarter. Finally, BNP Paribas Arbitrage SA acquired a new stake in Tesaro during the second quarter worth about $941,000. 88.81% of the stock is owned by institutional investors.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.